View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
DOJ/DEA | RIN: 1117-AB46 | Publication ID: Spring 2018 |
Title: Establishing Reporting Procedures for Purchasers and Suppliers to Follow in the Conduct of Double-Blind Studies | |
Abstract:
The Drug Enforcement Administration is proposing to update its regulations to establish a procedure for the use of the DEA Form 222 (DEA Official Order Form) in double-blind studies utilizing Schedule I or Schedule II controlled substances. |
|
Agency: Department of Justice(DOJ) | Priority: Substantive, Nonsignificant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: No | Unfunded Mandates: No |
EO 13771 Designation: Deregulatory | |
CFR Citation: 21 CFR 1305 | |
Legal Authority: 21 U.S.C. 821 21 U.S.C. 828 21 U.S.C. 871 |
Legal Deadline:
None |
||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: No | Federalism: No |
Included in the Regulatory Plan: No | |
Public Comment URL: www.regulations.gov/ | |
RIN Data Printed in the FR: No | |
Agency Contact: Michael J. Lewis Section Chief Department of Justice Drug Enforcement Administration 8701 Morrissette Drive, Springfield, VA 22152 Phone:202 598-6812 Fax:202 307-9536 |